MiNK Therapeutics, Inc. (NASDAQ:INKT – Free Report) – Analysts at HC Wainwright lifted their FY2026 earnings per share estimates for MiNK Therapeutics in a research note issued on Wednesday, November 11th. HC Wainwright analyst M. Keller now expects that the company will post earnings per share of ($2.29) for the year, up from their prior estimate of ($2.58). HC Wainwright has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for MiNK Therapeutics’ current full-year earnings is ($2.53) per share. HC Wainwright also issued estimates for MiNK Therapeutics’ Q4 2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($0.64) EPS.
Other equities research analysts have also recently issued research reports about the company. Zacks Research cut MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 12th. B. Riley Financial restated a “buy” rating and set a $50.00 price target (up from $43.00) on shares of MiNK Therapeutics in a research note on Wednesday, October 21st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MiNK Therapeutics in a report on Friday, October 2nd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $44.00.
Read Our Latest Stock Report on INKT
MiNK Therapeutics Stock Down 6.8%
INKT opened at $9.53 on Friday. MiNK Therapeutics has a fifty-two week low of $8.48 and a fifty-two week high of $16.93. The business has a 50-day moving average of $11.14 and a 200-day moving average of $11.21.
MiNK Therapeutics (NASDAQ:INKT – Get Free Report) last issued its earnings results on Wednesday, November 11th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.16. The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.07 million.
Insider Transactions at MiNK Therapeutics
In related news, CEO Jennifer Buell sold 6,938 shares of the stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the transaction, the chief executive officer owned 74,195 shares of the company’s stock, valued at $783,499.20. This represents a 8.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 20.40% of the stock is owned by company insiders.
About MiNK Therapeutics
MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.
Featured Articles
- Five stocks we like better than MiNK Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
